Cardio Diagnostics Holdings, Inc. (CDIOW) Stock Analysis

Company Overview

Cardio Diagnostics Holdings, Inc. focuses on the development and commercialization of epigenetics-based clinical tests designed specifically for the assessment of cardiovascular disease. The company operates within the healthcare technology sector, targeting the niche industry of cardiovascular diagnostics through the provision of specialized blood tests. According to available data, the company employs a workforce of 15 individuals to support its research and commercialization efforts. The market capitalization is listed as N/A, while the trailing twelve-month revenue stands at $14,825, figures that indicate the company operates on a very small scale relative to established market leaders.

Financial Health

The company reported a revenue of $14,825 for the trailing twelve months, yet this figure masks a significant deficit with a net income of $-6,498,167 and an EBITDA of $-6,085,950. The substantial gap between the minimal revenue and the large negative net income reveals an extremely aggressive cost structure where expenses vastly outweigh any income generated. Free cash flow stands at $-3,809,743, indicating that the company is currently burning cash and lacks the financial flexibility to fund operations from internal cash generation. Gross margin is reported at 100.0%, suggesting that the cost of goods sold is zero or negligible for the recognized revenue, while the operating margin is a negative -41159.6% and profit margin is 0.0%, highlighting severe operational inefficiencies or accounting anomalies in the reporting of costs relative to revenue. The company holds $5.11M in cash against $695,619 in debt, creating a situation where liquid assets significantly exceed liabilities, though the debt-to-equity ratio of 9.97 suggests a high level of leverage relative to shareholder equity. The current ratio is 9.79, which indicates a very strong short-term liquidity position where current assets are nearly ten times the value of current liabilities. Return on equity is -78.6% and return on assets is -44.1%, metrics that reveal that management is currently destroying value rather than generating returns for shareholders or utilizing assets efficiently.

Valuation Assessment

The trailing P/E and forward P/E ratios are both listed as N/A, which implies that without positive earnings, traditional price-to-earnings metrics cannot be calculated to assess the trajectory of expected earnings. The price-to-book ratio is 0.01, indicating that the market values the company at a fraction of its book value, reflecting a significant discount or a lack of market premium over the underlying net asset value. Alternative valuation metrics such as price-to-sales and EV/EBITDA are also N/A, suggesting that standard multiple-based valuation models are not applicable due to the company's financial structure or lack of profitability. The stock has a 52-week high of $0.02 and a 52-week low of $0.02, meaning the current price sits exactly at both the high and low of the trading range with no fluctuation observed during the year. The beta value is 2.23, which means the stock exhibits high price volatility, moving more than twice as much as the broader market in either direction.

Growth & Income

Revenue growth year-over-year is -21.2%, while earnings growth is N/A due to the lack of prior year profitability, implying that the company is currently in a contraction phase regarding top-line sales. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A, indicating that the company retains all earnings or cash flows rather than distributing them to shareholders. As a non-dividend payer, the company reinvests its limited resources or cash reserves into growth initiatives, research, and development rather than providing income to investors. The overall growth and income profile is characterized by declining revenue, negative earnings, and a reliance on cash reserves rather than operational profitability or dividend income.